Business Context and Reporting Period
This Form 8-K filing by Bio-Rad Laboratories, Inc. is dated March 24, 2010. The report addresses corporate governance changes, specifically the appointment of a new director to restore compliance with New York Stock Exchange (NYSE) listing standards.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to director compensation:
- Base Director Fee: $2,000 per month.
- Meeting Fee: $100 per board meeting for any meetings in excess of 16 per year.
- Audit Committee Fee: Additional $625 per month.
Material Changes
The primary material change is the appointment of Ted W. Love, M.D., to the Board of Directors and the Audit Committee on March 24, 2010. Dr. Love replaced Ruediger Naumann-Etienne, who resigned on December 4, 2009. This appointment restored the company's compliance with NYSE Section 303.A.07(a), which mandates three independent directors on the audit committee. Consequently, the "BC" (below compliance) indicator was removed from the company's ticker symbol on March 26, 2010.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk addressed was the potential loss of NYSE listing compliance due to the previous resignation of a director, which has now been resolved. Dr. Love is scheduled to stand for election at the annual meeting of stockholders on April 27, 2010.
Investor Verification Checklist
- Confirm the removal of the "BC" compliance indicator from the stock ticker.
- Verify Dr. Love's election status at the April 27, 2010, annual meeting.
- Review the attached press release (Exhibit 99.1) for any additional operational context not included in the 8-K text.